{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:15:13Z","timestamp":1780974913120,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bbrc.2024.150117","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T16:05:51Z","timestamp":1715702751000},"page":"150117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes"],"prefix":"10.1016","volume":"719","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-5299","authenticated-orcid":false,"given":"Shaoqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diange","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-6353","authenticated-orcid":false,"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2024.150117_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2024.150117_bib2","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bbrc.2024.150117_bib3","first-page":"7","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood, J. Am. Soc. Hematology"},{"key":"10.1016\/j.bbrc.2024.150117_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2024.150117_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2024.150117_bib6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/sj.leu.2403029","article-title":"Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family","volume":"17","author":"Shangary","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2024.150117_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"24","key":"10.1016\/j.bbrc.2024.150117_bib8","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and Azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2024.150117_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2024.150117_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nature cancer"},{"key":"10.1016\/j.bbrc.2024.150117_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41698-021-00209-9","article-title":"Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia","volume":"5","author":"White","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bbrc.2024.150117_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2024.150117_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2024.150117_bib14","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2024.150117_bib15","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2024.150117_bib16","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1039\/D0BM01547D","article-title":"Ultra-small platinum nanoparticles on gold nanorods induced intracellular ROS fluctuation to drive megakaryocytic differentiation of leukemia cells","volume":"8","author":"Wen","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bbrc.2024.150117_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41565-019-0406-1","article-title":"FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels","volume":"14","author":"Trujillo-Alonso","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbrc.2024.150117_bib18","first-page":"526","article-title":"A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia","volume":"18","author":"Kong","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbrc.2024.150117_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.colsurfb.2014.12.023","article-title":"Colloidal silver nanoparticles improve anti-leukemic drug efficacy via amplification of oxidative stress","volume":"126","author":"Guo","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.bbrc.2024.150117_bib20","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1021\/acs.chemrev.8b00626","article-title":"Reactive oxygen species (ROS)-Based nanomedicine","volume":"119","author":"Yang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbrc.2024.150117_bib21","first-page":"3322","article-title":"Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling","volume":"122","author":"Hole","year":"2013","journal-title":"Blood, J. Am. Soc. Hematology"},{"key":"10.1016\/j.bbrc.2024.150117_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202370187","article-title":"A selective nano cell cycle checkpoint inhibitor overcomes leukemia chemoresistance","volume":"19","author":"Sun","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2024.150117_bib23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2024.150117_bib24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2024.150117_bib25","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2024.150117_bib26","doi-asserted-by":"crossref","first-page":"33542","DOI":"10.1074\/jbc.M113.511170","article-title":"Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells","volume":"288","author":"Pei","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2024.150117_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121110","article-title":"Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy","volume":"277","author":"Niu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2024.150117_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-018-0797-0","article-title":"Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side","volume":"37","author":"Prieto-Bermejo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2024.150117_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10030498","article-title":"Characterization of NADPH oxidase expression and activity in acute myeloid leukemia cell lines: a correlation with the differentiation status","volume":"10","author":"Dakik","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbrc.2024.150117_bib30","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-16-2426","article-title":"Jab1\/Csn5-Thioredoxin signaling in relapsed acute monocytic leukemia under oxidative stress","volume":"23","author":"Zhou","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2024.150117_bib31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature08313","article-title":"Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation","volume":"461","author":"Owusu-Ansah","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2024.150117_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236003","article-title":"The role of reactive oxygen species in acute myeloid leukaemia","volume":"20","author":"Sillar","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24006533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24006533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T21:59:01Z","timestamp":1717279141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24006533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"alternative-id":["S0006291X24006533"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150117","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150117"}}